Patient Pool Forecasting
- Home
- epidemiology analysis
A Data-Driven
Epidemiology Forecasting Approach
With a robust methodology encompassing detailed literature reviews, extensive Key Opinion Leaders (KOLs) insights, and treatment monitoring, our epidemiology forecasting through 2034 integrates advanced data analytics, historical trends, and predictive modeling to deliver highly accurate projections. We provide detailed sub-segmentation across key demographic, geographic, and epidemiological variables, enabling clients to gain a granular understanding of disease trends. Coupled with our extensive network of KOLs including researchers, practitioners, and others, our approach ensures that our forecasts are not only data-backed but also enriched by the latest insights from experts in the field. Whether you're looking to understand disease burden, determine the target patient pool, anticipate patient needs, or design intervention strategies, or forecast how the prevalence is going to change in the coming decade and anticipate the impact of patient population over the years, DelveInsight's Epi Forecasting empowers you with the intelligence needed to stay ahead.
- 10-year Forecast
- Country Specific Projections
- Patient Burden Assessment
- Disease Segmentation
- Treatable Patient Segment with Highest Unmet Need (Mutation/or Protein expression/or Type-specific)
The Pharma Dilemma
Choosing the Right Patient Segment for Optimal Outcomes
At DelveInsight, we understand pharmaceutical and biotech companies' complexities in estimating and selecting the right patient segments for drug development. This critical decision is essential for achieving optimal outcomes while addressing challenges such as identifying the appropriate line of therapy, managing patient burden, assessing the impact of diagnosis, and calculating drug uptake share. We offer valuable insights and analytics to guide decision-making, helping companies identify and focus on patient populations with the highest unmet needs, ultimately fostering improved clinical outcomes and more efficient drug development.
Real-World Data
We integrate real-world evidence (RWE), epidemiological studies, and country-specific patient journey insights to refine target populations with precision.
Key Insights
Patient Demographics
Patient Burden
Prevalence/Incidence or Both
Diagnosis Rates and Trends
Disease Treatment Rate
Inclusion & Exclusion
Populations by Line of Therapy
Driving Diagnosis & Testing Rates
Epidem Forecasting
Patient Journey Insights
Robust epi forecasting and real-world patient journey insights to empower informed decision-making, enabling us to anticipate disease awareness, trends, and challenges in diagnosis and treatment, eventually optimizing patient-centric strategies effectively.
Country-wise Disease Patient Pool Forecasting
We offer comprehensive country-wise epidemiology segmentation, delivering in-depth insights into disease prevalence, incidence, and overall patient estimates. Our insights encompass 7MM and we also provide insights across other countries from APAC, LATAM, and MENA regions.
Understand Treatment Paradigms and Patient Journey
Gain insights into evolving treatment paradigms, updated treatment guidelines, recommendations, and incorporation along with patient journey, with DelveInsight's expertise, while understanding how physician prescribing patterns vary across countries for tailored strategies and improved outcomes.
Coverage Across Different Geographies
Leverage DelveInsight's vast KOL network for comprehensive epidemiology insights, even in data-scarce regions like LATAM and APAC.
Our Approach
Epidemiology Segmentation
Country-Specific Patient Trends
The robust methodologies deliver historical and forecasted data for indications upto 2034, segmented by country. The syndicated reports focus on 7MM, our team has rich experience in covering projects covering countries across the LATAM, APAC, and MENA regions.
Total Prevalent Cases
The comprehensive, data-driven methodology estimates the total prevalence or incidence of diseases within multiple therapy areas, tailored to each specific indication. The reports also provide valuable insights into survival, mortality, and morbidity rates.
Total Diagnosed Prevalent Cases
Thorough approaches to estimate the percentage of diagnosed cases from the estimated prevalent patient population, understanding misdiagnosed and undiagnosed populations, and identifying affecting changes in diagnosis trends, across different therapeutic areas.
Total Treated Cases
Comprehensive insights into the total treated cases, as, not all diagnosed patients receive appropriate treatment. Identifying the gap and challenges in receiving treatment and understanding disparities in access to targeted therapies across geographies
Analysis and Forecasting
Patient Burden
Advanced data insights and analytics to drive informed decision-making and strategic planning
Vast KOL Network
Unparalleled insights from various KOLs across different therapeutic areas
In-house Database
Reliable resources that enable us to deliver insightful and data-driven solutions.
Epidemiology Forecasting
Patient population forecasting upto 10 years inclusive of patient trends and analysis.
Coverage Across Various Geographies
In-depth epidemiological country-wise insights spanning across 20+ geographies.
Rare Disease Analysis
Track down the patient trends of ultra-rare disease with a vast network of KOLs.
100% Post Sale Support
One analyst per account for real-time support to provide assistance to our clients.
Request A Call Back
Case Studies
Success Story
-Epidemiology-Assessment-Across-15-Countries.png&w=2048&q=75)
Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment Across 15 Countries
Discover how we assisted a US client in evaluating the epidemiology of cSCC in solid organ transplant recipients across 15 countries.
-based-therapies.png&w=2048&q=75)
Target Patient Pool and Patient Segmentation for Interleukin-2-based Therapies
Dive deep and find out how we helped the client identify the optimal patient pool for IL-2-based therapies.
Epidemiology Forecast Analysis of Non-small Cell Lung Cancer (NSCLC): Trends and Insights
Find out how we helped in tracking epidemiological trends, risk factors, and projected incidence rates of NSCLC.
Epidem-Driven Insights
Why Epidem-based Models are Important and Better?
Advanced analytics to help organizations make data-driven decisions for effective public health strategies.
Data-Driven Planning
Exploring key factors shaping market potential through patient based scenario planning, leveraging patient trends to provide insightful and accurate future projections.
Dynamic Model
The Evergreen model enables the refinement and tweaking of various inputs, such as diagnosis, treatment, share uptake rates, and the assessment of their impact on patient populations and market segments, analyzed on a country-by-country basis.
Accurate Market Estimations
Precise market estimations by leveraging robust data analytics to identify treated population deriving revenue post considering multiple factors such as cost per patient, confidential discounts on list prices provided by pharma companies, price hikes & declines depending on country, & incorporation of expanded access programs into forecasting models to help predict market estimates accurately
Tailored Patient Journeys
The country-based patient journey provides insights into how patients navigate diagnosis, treatment, and care pathways, tailored to specific healthcare systems and cultural contexts.
Comprehensive Research Approach
A combination of primary and secondary research methodologies, reinforced by a robust data triangulation strategy, is utilized to deliver precise and actionable patient insights enabling pharma clients for strategic decision making.
Patient Burden Analysis
Analysis covering mortality, morbidity, prevalence, incidence, treated cases, and detailed patient pathways, enabling pharma and biotech companies to understand treatment complexities, evaluate market opportunities, optimize pricing and reimbursement, analyze competition, develop patient-centric treatments, and strategize effective market access for successful commercialization.